The Pharma Data

FEBRUARY 8, 2021

Janssen Announces Treatment with ERLEADA ® (apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer. The recruitment period for the study spanned from December 2015 to July 2017. 3 Dual primary endpoints of the study were OS and rPFS.1 About ERLEADA ® (apalutamide).

Treatment 52

Treatment Pharmaceutical Companies Therapies Pharmaceuticals 52

New Drug Approvals

OCTOBER 24, 2023

Molecular Weight: 631.700 FDA APPROVED, To treat moderately to severely active ulcerative colitis in adults, 10/12/2023 Velsipity Etrasimod , sold under the brand name Velsipity , is a medication that is used for the treatment of ulcerative colitis (UC). [1] Peyrin-Biroulet L, Christopher R, Behan D, Lassen C (May 2017).

FDA 57

FDA FDA Approval International Pharmacokinetics 57

The Pharma Data

NOVEMBER 15, 2020

. “Guidelines recommend that psychosocial services are used before antipsychotic treatment and that children are carefully assessed before initiating antipsychotics,” Bushnell said in a university news release. In recent years, pervasive developmental disorders (PDD) accounted for the most antipsychotic prescribing.

FDA Approval 52

FDA Approval Doctors Treatment Therapies 52

Advarra

AUGUST 16, 2022

Food and Drug Administration (FDA) approval. Since then, the FDA has significantly changed its approach to rare and orphan diseases. The FDA Since 1983. The Orphan Drug Act of 1983 was instrumental in changing the number of orphan drugs approved in the U.S. Before 1983, only 38 orphan drugs had received U.S.

Disease 52

Disease Clinical Trials FDA Approval FDA 52

The Pharma Data

NOVEMBER 15, 2020

Urovant’s lead drug candidate, vibegron, is an oral, once-daily small molecule beta-3 agonist being evaluated for the treatment of OAB, abdominal pain associated with irritable bowel syndrome (IBS) in men with OAB, and for men suffering from OAB with benign prostatic hyperplasia (BPH).

Science 52

Science Small Molecule FDA Approval Therapies 52

The Pharma Data

DECEMBER 18, 2020

Roxadustat is approved in China, Japan (under the name Evrenzo), and Chile for the treatment of anemia in CKD in non-dialysis dependent (NDD) and dialysis-dependent (DD) adult patients. Global, regional, and national burden of chronic kidney disease, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017.

Disease 52

Disease FDA FDA Approval Treatment 52

The Pharma Data

APRIL 4, 2022

If approved, Dupixent would be the first medicine available in the U.S. living with eosinophilic esophagitis who are currently treated, of whom approximately 48,000 have failed multiple treatments. FDA granted Breakthrough Therapy designation to Dupixent for the treatment of patients aged 12 years and older with EoE.

FDA 52

FDA Treatment Disease FDA Approval 52

The Pharma Data

AUGUST 22, 2021

today announced that Opdivo ® (nivolumab) 240 mg every two weeks or 480 mg every four weeks (injection for intravenous use) was approved by the U.S. 1 The approval is based on the Phase 3 CheckMate -274 trial, which compared Opdivo 240 mg (n=353) to placebo (n=356). months [95% Confidence Interval (CI): 16.5 months [95% CI: 8.3

FDA Approval 52

FDA Approval Disease Treatment Trials 52

The Pharma Data

AUGUST 25, 2020

While we are disappointed by the outcome of the IDHENTIFY study, we remain confident in IDHIFA ’s established role as a treatment option for patients with relapsed or refractory AML with an IDH2 mutation and are grateful to all those who participated in the study,” said Noah Berkowitz, M.D., Food and Drug Administration (FDA)-approved test.

Trials 52

Trials FDA Approval Therapies Treatment 52

The Pharma Data

OCTOBER 15, 2020

John Hospital, researchers compared 649 patients from two cohorts: a recent cohort (2017–2019) from the RECOVER III post-market approval (PMA) study, after the widespread adoption of the best practice of placing Impella pre-PCI, and a cohort from before PMA (2008–2014) when the practice of placing Impella pre-PCI was not yet widely adopted.

Hospitals 52

Hospitals FDA Approval FDA Treatment 52

Drug Target Review

JULY 5, 2024

Recently, a network-based drug-screening platform has been developed to test FDA-approved drugs for Alzheimer’s disease (AD) using 1,300 iPSC-derived organoids from 11 sporadic AD patients. 545:54-59 (2017). A regenerative approach to the treatment of multiple sclerosis. Molecular Autism. link] Birey F, et al.

Targeted Protein Degradation 65

Targeted Protein Degradation Drugs Disease FDA Approval 65

The Pharma Data

JUNE 18, 2021

June 8, 2021 /PRNewswire/ — Allergan Aesthetics, an AbbVie company (NYSE: ABBV ), is changing the way BOTOX ® Cosmetic, the #1 selling neurotoxin treatment 1 , is connecting with consumers. IRVINE, Calif. Experience the interactive Multimedia News Release here: [link] . Each story is unique. Each story is unique.

Doctors 52

Doctors FDA Approval Treatment Production 52

The Pharma Data

SEPTEMBER 28, 2021

additionally , all five babies maintained the power to swallow and were ready to feed exclusively orally after 12 months of treatment. Food and Drug Administration (FDA) and European Medicines Agency (EMA) approved Evrysdi for the treatment of SMA in adults and youngsters 2 months aged and older.

Clinical Trials 52

Clinical Trials Protein Expression Therapies FDA 52

Agency IQ

JANUARY 19, 2024

However, this is actually relatively aligned with the number of new active substances seen prior to and during the first year of the pandemic: 39 in 2020 ; 30 in 2019 ; 42 in 2018 and 35 in 2017. FDA in October 2023. The product was approved in the E.U. received a CRL from the FDA in May 2023 due to manufacturing control issues.

Biosimilars 40

Biosimilars FDA Production Treatment 40

Metabolite Tales Blog

JANUARY 23, 2024

Metabolism of 2023 FDA Approved Small Molecules – PART 1 By Julia Shanu-Wilson 2023 was a fruitful year for drug approvals by the FDA, with a crop of 34 small molecules out of a total of 55 new drugs [1]. link] [5] FDA prescribing information for fezolinetant. Health Sci Rep. 6(10):e1610.

Small Molecule 52

Small Molecule FDA Approval FDA Pharmacokinetics 52

FDA Law Blog: Biosimilars

FEBRUARY 29, 2024

The use of a surrogate endpoint can considerably shorten the time required prior to receiving FDA approval. If the confirmatory trial shows that the drug actually provides a clinical benefit, then the FDA grants traditional approval for the drug. 8,128,929 [] for [PTE] request under 35 U.S.C. §

FDA 59

FDA Production FDA Approval Compliance 59

FDA Law Blog: Biosimilars

JULY 24, 2023

This time, rather than use codes and patent certifications, the fight is over orphan drug exclusivity (“ODE”), with Jazz challenging FDA’s clinical superiority decision concerning sodium oxybate in the treatment of narcolepsy.

FDA 52

FDA Regulations Clinical Trials Production 52

The Pharma Data

DECEMBER 8, 2020

CEO and founder Min Li knows a thing or two from his time running GSK’s neuro R&D group before the company shuttered the program in 2017. Pear’s reSET, reSET-O and Somryst are the first PDTs to receive FDA approval for treating disease. The impact of CNS diseases extends beyond patients—to their families and society as well.”

RNA 52

RNA Therapies Disease Protein Expression 52

The Pharma Data

AUGUST 27, 2020

FoundationOne Liquid CDx analyses more than 300 cancer-related genes and multiple genomic signatures to help inform treatment decisions for all solid tumour cancers. The convenience of testing a blood sample may also enable more rapid treatment decisions, so that patients can feel reassured they are not losing time to fight their disease.”.

FDA Approval 52

FDA Approval FDA DNA Therapies 52

The Pharma Data

MAY 18, 2021

5 percent of the tumour area) as determined by an FDA-approved test or are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status. Roche remains committed to following the science to better understand cancer, including which patients may benefit most from immunotherapy treatment.

FDA 52

FDA Treatment Pharmaceuticals Science 52

The Pharma Data

MARCH 16, 2021

Durability: 1,2 Robust joint and skin response rates and mean improvements from baseline in outcome measures were maintained through two years, and approximately 90 percent of patients randomized to TREMFYA q4w or q8w continued treatment with TREMFYA through Week 100. TREMFYA was approved in the U.S. TREMFYA was approved in the U.S.

Treatment 52

Treatment Disease Pharmacokinetics Therapies 52

NIH Director's Blog: Drug Development

JULY 20, 2017

Specifically, after 2 to 4 weeks of treatment with this combination of two correctors and a potentiator, such patients experienced about a 10 percentage point improvement in forced expiratory volume in 1 second (FEV1), which is a key measure of lung capacity. Cystic Fibrosis Foundation News Release, July 18, 2017.

Clinical Trials 52

Clinical Trials Small Molecule Therapies Disease 52

Alta Sciences

APRIL 17, 2024

Five Promising Treatment Areas in Early-Phase Drug Development in 2024 aasimakopoulos Wed, 04/17/2024 - 15:52 Early-phase drug development is an ever-changing landscape, as emerging science leads to new promising areas of research for the treatment of human health issues.

Drug Development 52

Drug Development Treatment FDA Approval Therapies 52

The Pharma Data

SEPTEMBER 10, 2021

Long-Term Real-World Effectiveness of Carbidopa/Levodopa Enteral Suspension After 36 Months of Treatment Initiation: Final Results from PROviDE Study. OnabotulinumtoxinA Treatment in Patients with Upper Limb and Lower Limb Spasticity from the ASPIRE Study. BOTOX ® Abstracts.

Doctors 52

Doctors Clinical Trials Disease Therapies 52

The Pharma Data

JANUARY 21, 2021

In 2017, Regeneron became only the third sponsor of the Science Talent Search, increasing the overall awards distribution to better reward the best and brightest young minds. Unique among high school competitions in the U.S. Through its 10-year, $100 million commitment, Regeneron nearly doubled the overall award distribution to $3.1

Science 40

Science Engineering Molecular Biology Bioinformatics 40

The Pharma Data

JUNE 18, 2021

“We are dedicated to helping more people living with rheumatoid arthritis reach their treatment goals aimed at remission or low disease activity,” said Mudra Kapoor, M.D., Efficacy data reported based on randomized treatment groups. 100PY on HUMIRA, including non-treatment emergent deaths. years of treatment.

Treatment 40

Treatment Therapies Disease Clinical Trials 40

Agency IQ

SEPTEMBER 15, 2023

Until recently, the FDA relied on a monograph process through which firms could bring OTC drugs to market without FDA approval so long as it adhered to pre-set terms under the monograph. The FDA will follow these procedures for both agency-initiated operations (e.g.,

Science 40

Science FDA Clinical Trials Clinical Pharmacology 40

Broad Institute

OCTOBER 11, 2023

Manguso, who’d recently graduated from college and was conducting research at the University of Copenhagen as a Fulbright scholar, moved back to the Boston area to be with his mother as she underwent treatment. His mother had a presentation of the disease that suggested her immune system was already on the job.

Research 137

Research Immune Response Clinical Trials Therapies 137

The Pharma Data

JUNE 18, 2021

Food and Drug Administration (FDA) has approved PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) for the prevention of invasive disease and pneumonia caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes in the vaccine in adults ages 18 years and older. Following today’s FDA approval, the U.S.

Vaccine 52

Vaccine FDA Approval FDA Disease 52

The Pharma Data

SEPTEMBER 10, 2020

Photo by the CDC/FDA. The FDA has approved a new indication of Trelegy Ellipta for the treatment of asthma and patients with chronic obstructive pulmonary disease. . Today’s approval is an important advance for these patients as it allows them to benefit from triple therapy by using one inhaler, once a day.”.

FDA Approval 52

FDA Approval FDA Disease Therapies 52

New Drug Approvals

AUGUST 26, 2023

Zuranolone CAS 1632051-40-1 Zurzuvae FDA APPROVED 8/4/2023, To treat postpartum depression Press Release WeightAverage: 409.574 Monoisotopic: 409.272927379Chemical FormulaC 25 H 35 N 3 O 2 SAGE 217 SAGE-217 SAGE217 Zuranolone , sold under the brand name Zurzuvae , is a medication used for the treatment of postpartum depression. [1]

FDA 52

FDA FDA Approval Clinical Trials Treatment 52

The Pharma Data

JANUARY 5, 2021

“Benuvia is excited to partner with the leadership of Radius Health to progress the late-stage development and commercialization of our synthetic cannabidiol oral solution for the treatment of rare and underserved diseases. We look forward to supporting Radius through our U.S. Davis, executive chairman of Benuvia. Benuvia Therapeutics Inc.

Disease 52

Disease FDA Approval Clinical Trials Trials 52

Agency IQ

MAY 17, 2024

The bill is effectively a successor to the RACE for Children Act of 2017, which became law as part of the FDA Reauthorization Act of 2017 (FDARA). The law required some drug sponsors to assess the efficacy of adult cancer treatments in children under specific conditions. DORIS MATSUI (D-Calif.) and GUS BILIRAKIS (R-Fla.),

FDA 40

FDA Disease FDA Approval Production 40

Vial

JUNE 12, 2024

As the names imply, disease-specific PROs measure features specific to a disease or syndrome, while condition-specific PROs describe aspects of a particular condition, intervention, or treatment not uniquely associated with one disease. Such complications may otherwise be missed if only disease-specific PROs are used.

Clinical Trials 52

Clinical Trials Trials FDA Clinical Research 52

Drug Target Review

JUNE 21, 2023

4 For the treatment of rare genetic disorders especially, drugs with genetically supported targets are more than twice as likely to be approved 5 , thereby indicating genetics and genomics can empower companies to develop better drugs. 2017 Mar 29;9(383):eaag1166. Sci Transl Med. Doi: 10.1126/scitranslmed.aag1166.

Disease 112

Disease Clinical Trials Therapies Science 112

Drug Target Review

AUGUST 3, 2023

Precision medicine , with its focus on personalised treatments tailored to an individual’s genetic makeup, has seen remarkable progress in recent years. What preclinical research methods are commonly employed in precision medicine, and how do they contribute to the development of personalised treatments?

DNA 52

DNA Clinical Trials Trials Disease 52

Vial

DECEMBER 5, 2023

In 2017, the Food & Drug Administration (FDA) approved the first gene therapy for cancer and for inherited diseases, the first multiplex NGS panel for companion diagnostics (CDx), and the first drug targeting a genetic signature though not a disease. Fountzilas et al. Satam et al.

Clinical Trials 52

Clinical Trials Trials RNA Bioinformatics 52